UA126270C2 - Мутеїни інтерлейкіну-2 для росту регуляторних t-клітин - Google Patents

Info

Publication number

UA126270C2

UA126270C2 UAA201710936A UAA201710936A UA126270C2 UA 126270 C2 UA126270 C2 UA 126270C2 UA A201710936 A UAA201710936 A UA A201710936A UA A201710936 A UAA201710936 A UA A201710936A UA 126270 C2 UA126270 C2 UA 126270C2

Authority

UA

Ukraine

Prior art keywords

rgo

mutein

cells

mai

shi

Prior art date

2015-04-10

Links

• Espacenet
• Global Dossier
• Discuss

• 108010002350 Interleukin-2 Proteins 0.000 title claims abstract description 361
• 102000000588 Interleukin-2 Human genes 0.000 title claims abstract description 361
• 210000003289 regulatory T cell Anatomy 0.000 title claims description 46
• 210000004027 cell Anatomy 0.000 claims abstract description 214
• 238000000034 method Methods 0.000 claims abstract description 112
• 239000000203 mixture Substances 0.000 claims abstract description 44
• 238000006206 glycosylation reaction Methods 0.000 claims abstract description 29
• 230000013595 glycosylation Effects 0.000 claims abstract description 28
• 230000002829 reductive effect Effects 0.000 claims abstract description 26
• 239000012636 effector Substances 0.000 claims abstract description 24
• 210000004962 mammalian cell Anatomy 0.000 claims abstract description 20
• 108090000623 proteins and genes Proteins 0.000 claims description 372
• 102000004169 proteins and genes Human genes 0.000 claims description 278
• 150000007523 nucleic acids Chemical class 0.000 claims description 121
• 102000039446 nucleic acids Human genes 0.000 claims description 116
• 108020004707 nucleic acids Proteins 0.000 claims description 116
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 104
• 230000035772 mutation Effects 0.000 claims description 92
• 108020001507 fusion proteins Proteins 0.000 claims description 84
• 102000037865 fusion proteins Human genes 0.000 claims description 84
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 74
• 230000001965 increasing effect Effects 0.000 claims description 63
• 238000006467 substitution reaction Methods 0.000 claims description 57
• 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims description 55
• 230000004044 response Effects 0.000 claims description 43
• 210000005259 peripheral blood Anatomy 0.000 claims description 39
• 239000011886 peripheral blood Substances 0.000 claims description 38
• 230000008859 change Effects 0.000 claims description 34
• 238000011282 treatment Methods 0.000 claims description 34
• 230000014509 gene expression Effects 0.000 claims description 33
• 210000000822 natural killer cell Anatomy 0.000 claims description 32
• 230000006870 function Effects 0.000 claims description 26
• 239000013598 vector Substances 0.000 claims description 25
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 24
• 241000699670 Mus sp. Species 0.000 claims description 22
• 210000004899 c-terminal region Anatomy 0.000 claims description 22
• 230000037430 deletion Effects 0.000 claims description 22
• 238000012217 deletion Methods 0.000 claims description 22
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 21
• 239000004472 Lysine Substances 0.000 claims description 21
• 208000023275 Autoimmune disease Diseases 0.000 claims description 18
• 230000007423 decrease Effects 0.000 claims description 18
• 239000013604 expression vector Substances 0.000 claims description 17
• 208000027866 inflammatory disease Diseases 0.000 claims description 16
• 235000010469 Glycine max Nutrition 0.000 claims description 15
• 210000004369 blood Anatomy 0.000 claims description 14
• 239000008280 blood Substances 0.000 claims description 14
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
• 201000010099 disease Diseases 0.000 claims description 13
• 230000002757 inflammatory effect Effects 0.000 claims description 13
• 230000036760 body temperature Effects 0.000 claims description 12
• 230000035755 proliferation Effects 0.000 claims description 12
• 108010088751 Albumins Proteins 0.000 claims description 11
• 206010047115 Vasculitis Diseases 0.000 claims description 11
• 239000003795 chemical substances by application Substances 0.000 claims description 11
• 102000009027 Albumins Human genes 0.000 claims description 10
• 244000068988 Glycine max Species 0.000 claims description 10
• 241000699666 Mus <mouse, genus> Species 0.000 claims description 10
• 238000004321 preservation Methods 0.000 claims description 9
• 239000000126 substance Substances 0.000 claims description 9
• 208000006673 asthma Diseases 0.000 claims description 8
• 238000011577 humanized mouse model Methods 0.000 claims description 8
• 210000000440 neutrophil Anatomy 0.000 claims description 8
• 208000005176 Hepatitis C Diseases 0.000 claims description 7
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
• 201000004681 Psoriasis Diseases 0.000 claims description 7
• 239000007924 injection Substances 0.000 claims description 7
• 150000002500 ions Chemical class 0.000 claims description 7
• 230000009467 reduction Effects 0.000 claims description 7
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
• 206010000234 Abortion spontaneous Diseases 0.000 claims description 6
• 208000012657 Atopic disease Diseases 0.000 claims description 6
• 108700026244 Open Reading Frames Proteins 0.000 claims description 6
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
• 238000012258 culturing Methods 0.000 claims description 6
• 239000000539 dimer Substances 0.000 claims description 6
• 210000003527 eukaryotic cell Anatomy 0.000 claims description 6
• 208000024908 graft versus host disease Diseases 0.000 claims description 6
• 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 6
• 206010025135 lupus erythematosus Diseases 0.000 claims description 6
• 201000006417 multiple sclerosis Diseases 0.000 claims description 6
• 210000001236 prokaryotic cell Anatomy 0.000 claims description 6
• 150000003839 salts Chemical class 0.000 claims description 6
• 208000000995 spontaneous abortion Diseases 0.000 claims description 6
• 238000012360 testing method Methods 0.000 claims description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
• 201000001320 Atherosclerosis Diseases 0.000 claims description 5
• 241000699802 Cricetulus griseus Species 0.000 claims description 5
• 208000009329 Graft vs Host Disease Diseases 0.000 claims description 5
• 208000021386 Sjogren Syndrome Diseases 0.000 claims description 5
• 206010052779 Transplant rejections Diseases 0.000 claims description 5
• 238000001514 detection method Methods 0.000 claims description 5
• 238000011534 incubation Methods 0.000 claims description 5
• 210000001672 ovary Anatomy 0.000 claims description 5
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
• 208000009137 Behcet syndrome Diseases 0.000 claims description 4
• 108010074051 C-Reactive Protein Proteins 0.000 claims description 4
• 102100032752 C-reactive protein Human genes 0.000 claims description 4
• 241001547860 Gaya Species 0.000 claims description 4
• 208000024711 extrinsic asthma Diseases 0.000 claims description 4
• 239000007789 gas Substances 0.000 claims description 4
• 102000055277 human IL2 Human genes 0.000 claims description 4
• 230000035939 shock Effects 0.000 claims description 4
• 208000024891 symptom Diseases 0.000 claims description 4
• 238000005406 washing Methods 0.000 claims description 4
• 241000196324 Embryophyta Species 0.000 claims description 3
• 101100182729 Homo sapiens LY6K gene Proteins 0.000 claims description 3
• 102100032129 Lymphocyte antigen 6K Human genes 0.000 claims description 3
• 206010028980 Neoplasm Diseases 0.000 claims description 3
• 101100491259 Oryza sativa subsp. japonica AP2-2 gene Proteins 0.000 claims description 3
• 241001602688 Pama Species 0.000 claims description 3
• 230000009471 action Effects 0.000 claims description 3
• 230000006229 amino acid addition Effects 0.000 claims description 3
• 229910052799 carbon Inorganic materials 0.000 claims description 3
• 235000013305 food Nutrition 0.000 claims description 3
• 230000036961 partial effect Effects 0.000 claims description 3
• MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 claims description 3
• 235000017788 Cydonia oblonga Nutrition 0.000 claims description 2
• 208000010201 Exanthema Diseases 0.000 claims description 2
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 2
• 230000036528 appetite Effects 0.000 claims description 2
• 235000019789 appetite Nutrition 0.000 claims description 2
• 201000005884 exanthem Diseases 0.000 claims description 2
• 238000012544 monitoring process Methods 0.000 claims description 2
• 229910052700 potassium Inorganic materials 0.000 claims description 2
• 206010037844 rash Diseases 0.000 claims description 2
• 210000001550 testis Anatomy 0.000 claims description 2
• 244000005894 Albizia lebbeck Species 0.000 claims 11
• 235000013405 beer Nutrition 0.000 claims 10
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 8
• 235000008001 rakum palm Nutrition 0.000 claims 6
• 240000005546 Piper methysticum Species 0.000 claims 5
• 235000016787 Piper methysticum Nutrition 0.000 claims 5
• 241000159610 Roya <green alga> Species 0.000 claims 5
• 229910052757 nitrogen Inorganic materials 0.000 claims 5
• 206010010071 Coma Diseases 0.000 claims 4
• 241001442654 Percnon planissimum Species 0.000 claims 4
• 101100209990 Rattus norvegicus Slc18a2 gene Proteins 0.000 claims 4
• 206010040007 Sense of oppression Diseases 0.000 claims 4
• 235000015076 Shorea robusta Nutrition 0.000 claims 4
• 241000289690 Xenarthra Species 0.000 claims 4
• 244000145841 kine Species 0.000 claims 4
• 210000002445 nipple Anatomy 0.000 claims 4
• 239000005020 polyethylene terephthalate Substances 0.000 claims 4
• 241001556567 Acanthamoeba polyphaga mimivirus Species 0.000 claims 3
• 241000543381 Cliftonia monophylla Species 0.000 claims 3
• 235000003913 Coccoloba uvifera Nutrition 0.000 claims 3
• 235000013162 Cocos nucifera Nutrition 0.000 claims 3
• 244000060011 Cocos nucifera Species 0.000 claims 3
• 101100234002 Drosophila melanogaster Shal gene Proteins 0.000 claims 3
• 235000008247 Echinochloa frumentacea Nutrition 0.000 claims 3
• 241000581652 Hagenia abyssinica Species 0.000 claims 3
• 241001026509 Kata Species 0.000 claims 3
• 241000087799 Koma Species 0.000 claims 3
• 241001214257 Mene Species 0.000 claims 3
• 240000004072 Panicum sumatrense Species 0.000 claims 3
• 241001659863 Panna Species 0.000 claims 3
• 241001377010 Pila Species 0.000 claims 3
• 240000008976 Pterocarpus marsupium Species 0.000 claims 3
• 235000011449 Rosa Nutrition 0.000 claims 3
• 244000166071 Shorea robusta Species 0.000 claims 3
• 241001655798 Taku Species 0.000 claims 3
• 241000607479 Yersinia pestis Species 0.000 claims 3
• 239000006071 cream Substances 0.000 claims 3
• 210000004209 hair Anatomy 0.000 claims 3
• 229920000139 polyethylene terephthalate Polymers 0.000 claims 3
• WKBPZYKAUNRMKP-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)pentyl]1,2,4-triazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(CCC)CN1C=NC=N1 WKBPZYKAUNRMKP-UHFFFAOYSA-N 0.000 claims 2
• 241001116389 Aloe Species 0.000 claims 2
• 241001132374 Asta Species 0.000 claims 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
• 244000075850 Avena orientalis Species 0.000 claims 2
• 235000007319 Avena orientalis Nutrition 0.000 claims 2
• 235000010893 Bischofia javanica Nutrition 0.000 claims 2
• 240000005220 Bischofia javanica Species 0.000 claims 2
• OIOQREYBGDAYGT-UHFFFAOYSA-N C(C)N(CCN1C(=NC2=C1C=CC(=C2)[N+](=O)[O-])CC1=CC=C(C=C1)OC(C)C)CC Chemical compound C(C)N(CCN1C(=NC2=C1C=CC(=C2)[N+](=O)[O-])CC1=CC=C(C=C1)OC(C)C)CC OIOQREYBGDAYGT-UHFFFAOYSA-N 0.000 claims 2
• 241000282461 Canis lupus Species 0.000 claims 2
• 241000283707 Capra Species 0.000 claims 2
• 241000283153 Cetacea Species 0.000 claims 2
• 235000008733 Citrus aurantifolia Nutrition 0.000 claims 2
• 241001327708 Coriaria sarmentosa Species 0.000 claims 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
• 244000089409 Erythrina poeppigiana Species 0.000 claims 2
• 235000008730 Ficus carica Nutrition 0.000 claims 2
• 244000025361 Ficus carica Species 0.000 claims 2
• 241000102542 Kara Species 0.000 claims 2
• 235000012093 Myrtus ugni Nutrition 0.000 claims 2
• 241000468053 Obodhiang virus Species 0.000 claims 2
• 241000283965 Ochotona princeps Species 0.000 claims 2
• 235000016496 Panda oleosa Nutrition 0.000 claims 2
• 240000000220 Panda oleosa Species 0.000 claims 2
• 241000282320 Panthera leo Species 0.000 claims 2
• 206010035148 Plague Diseases 0.000 claims 2
• 241000183024 Populus tremula Species 0.000 claims 2
• 240000001987 Pyrus communis Species 0.000 claims 2
• 235000009776 Rathbunia alamosensis Nutrition 0.000 claims 2
• 244000258044 Solanum gilo Species 0.000 claims 2
• 235000018650 Solanum gilo Nutrition 0.000 claims 2
• 241001415849 Strigiformes Species 0.000 claims 2
• 241001424341 Tara spinosa Species 0.000 claims 2
• 244000061461 Tema Species 0.000 claims 2
• 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 claims 2
• 240000006909 Tilia x europaea Species 0.000 claims 2
• 235000011941 Tilia x europaea Nutrition 0.000 claims 2
• 241001343083 Tonna Species 0.000 claims 2
• CCAZWUJBLXKBAY-ULZPOIKGSA-N Tutin Chemical compound C([C@]12[C@@H]3O[C@@H]3[C@@]3(O)[C@H]4C(=O)O[C@@H]([C@H]([C@]32C)O)[C@H]4C(=C)C)O1 CCAZWUJBLXKBAY-ULZPOIKGSA-N 0.000 claims 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
• 241000700647 Variola virus Species 0.000 claims 2
• 206010000496 acne Diseases 0.000 claims 2
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 2
• 235000011399 aloe vera Nutrition 0.000 claims 2
• GJJYZOBRHIMORS-GQOAHPRESA-K aloglutamol Chemical compound OCC(N)(CO)CO.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O[Al](O)O GJJYZOBRHIMORS-GQOAHPRESA-K 0.000 claims 2
• QXAITBQSYVNQDR-UHFFFAOYSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1N=CN(C)C=NC1=CC=C(C)C=C1C QXAITBQSYVNQDR-UHFFFAOYSA-N 0.000 claims 2
• 244000240602 cacao Species 0.000 claims 2
• 201000011510 cancer Diseases 0.000 claims 2
• 235000013351 cheese Nutrition 0.000 claims 2
• 230000035622 drinking Effects 0.000 claims 2
• 210000000744 eyelid Anatomy 0.000 claims 2
• 239000003925 fat Substances 0.000 claims 2
• 235000011389 fruit/vegetable juice Nutrition 0.000 claims 2
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 2
• KEBHLNDPKPIPLI-UHFFFAOYSA-N hydron;2-(3h-inden-4-yloxymethyl)morpholine;chloride Chemical compound Cl.C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 KEBHLNDPKPIPLI-UHFFFAOYSA-N 0.000 claims 2
• 239000004571 lime Substances 0.000 claims 2
• 235000000010 nanu Nutrition 0.000 claims 2
• 244000082862 nanu Species 0.000 claims 2
• 229910052761 rare earth metal Inorganic materials 0.000 claims 2
• 210000003296 saliva Anatomy 0.000 claims 2
• 239000004576 sand Substances 0.000 claims 2
• 229910052718 tin Inorganic materials 0.000 claims 2
• 239000011031 topaz Substances 0.000 claims 2
• 229910052853 topaz Inorganic materials 0.000 claims 2
• JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 claims 2
• 210000003462 vein Anatomy 0.000 claims 2
• 230000001755 vocal effect Effects 0.000 claims 2
• WDGXQSVUSMTYNG-UHFFFAOYSA-N 2-Methyl-3-(2-methylphenyl)-3,4-dihydroquinazolin-4-one [2-(diphenylmethoxy)ethyl]dimethylamine hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1.CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C WDGXQSVUSMTYNG-UHFFFAOYSA-N 0.000 claims 1
• KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 claims 1
• WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims 1
• IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 claims 1
• CUCUKLJLRRAKFN-UHFFFAOYSA-N 7-Hydroxy-(S)-usnate Chemical compound CC12C(=O)C(C(=O)C)C(=O)C=C1OC1=C2C(O)=C(C)C(O)=C1C(C)=O CUCUKLJLRRAKFN-UHFFFAOYSA-N 0.000 claims 1
• 241001290610 Abildgaardia Species 0.000 claims 1
• 241001143500 Aceraceae Species 0.000 claims 1
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 1
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 1
• 102100039164 Acetyl-CoA carboxylase 1 Human genes 0.000 claims 1
• 208000002874 Acne Vulgaris Diseases 0.000 claims 1
• ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims 1
• 235000001674 Agaricus brunnescens Nutrition 0.000 claims 1
• 241001182632 Akko Species 0.000 claims 1
• 241001136792 Alle Species 0.000 claims 1
• 235000011746 Amaranthus hypochondriacus Nutrition 0.000 claims 1
• 240000003147 Amaranthus hypochondriacus Species 0.000 claims 1
• 241001135961 Amsacta moorei entomopoxvirus Species 0.000 claims 1
• 235000007119 Ananas comosus Nutrition 0.000 claims 1
• 244000099147 Ananas comosus Species 0.000 claims 1
• 241000409324 Anisus Species 0.000 claims 1
• 241000272814 Anser sp. Species 0.000 claims 1
• 241000584629 Aosa Species 0.000 claims 1
• 241000880621 Ascarina lucida Species 0.000 claims 1
• 206010003445 Ascites Diseases 0.000 claims 1
• 241001581492 Attila Species 0.000 claims 1
• 241000972773 Aulopiformes Species 0.000 claims 1
• 241001657091 Avima Species 0.000 claims 1
• 101100165218 Bacillus subtilis (strain 168) bceR gene Proteins 0.000 claims 1
• 241000566113 Branta sandvicensis Species 0.000 claims 1
• OWNRRUFOJXFKCU-UHFFFAOYSA-N Bromadiolone Chemical compound C=1C=C(C=2C=CC(Br)=CC=2)C=CC=1C(O)CC(C=1C(OC2=CC=CC=C2C=1O)=O)C1=CC=CC=C1 OWNRRUFOJXFKCU-UHFFFAOYSA-N 0.000 claims 1
• 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 claims 1
• 244000025254 Cannabis sativa Species 0.000 claims 1
• 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims 1
• 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims 1
• 235000002566 Capsicum Nutrition 0.000 claims 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
• UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims 1
• 102100027835 Cell death regulator Aven Human genes 0.000 claims 1
• 241000700114 Chinchillidae Species 0.000 claims 1
• 241000251730 Chondrichthyes Species 0.000 claims 1
• 241000511343 Chondrostoma nasus Species 0.000 claims 1
• 241001342895 Chorus Species 0.000 claims 1
• 240000000560 Citrus x paradisi Species 0.000 claims 1
• 241000254173 Coleoptera Species 0.000 claims 1
• 235000004257 Cordia myxa Nutrition 0.000 claims 1
• 244000157795 Cordia myxa Species 0.000 claims 1
• 229920000742 Cotton Polymers 0.000 claims 1
• ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims 1
• 235000018782 Dacrydium cupressinum Nutrition 0.000 claims 1
• 240000006055 Dacrydium cupressinum Species 0.000 claims 1
• 241000283014 Dama Species 0.000 claims 1
• 235000008597 Diospyros kaki Nutrition 0.000 claims 1
• 244000236655 Diospyros kaki Species 0.000 claims 1
• 101100369915 Drosophila melanogaster stas gene Proteins 0.000 claims 1
• 101100258093 Drosophila melanogaster stum gene Proteins 0.000 claims 1
• 206010072268 Drug-induced liver injury Diseases 0.000 claims 1
• 101150076104 EAT2 gene Proteins 0.000 claims 1
• 102100021807 ER degradation-enhancing alpha-mannosidase-like protein 1 Human genes 0.000 claims 1
• 241001061260 Emmelichthys struhsakeri Species 0.000 claims 1
• 241000283074 Equus asinus Species 0.000 claims 1
• 102100035261 FYN-binding protein 1 Human genes 0.000 claims 1
• 108091011190 FYN-binding protein 1 Proteins 0.000 claims 1
• 241000282326 Felis catus Species 0.000 claims 1
• 238000006424 Flood reaction Methods 0.000 claims 1
• 241000237858 Gastropoda Species 0.000 claims 1
• 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 claims 1
• 241001425722 Greta Species 0.000 claims 1
• 241000989913 Gunnera petaloidea Species 0.000 claims 1
• 241000258937 Hemiptera Species 0.000 claims 1
• 208000031361 Hiccup Diseases 0.000 claims 1
• 101000963424 Homo sapiens Acetyl-CoA carboxylase 1 Proteins 0.000 claims 1
• 101000698131 Homo sapiens Cell death regulator Aven Proteins 0.000 claims 1
• 101000895701 Homo sapiens ER degradation-enhancing alpha-mannosidase-like protein 1 Proteins 0.000 claims 1
• 101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 claims 1
• 101000589632 Homo sapiens N-acetylaspartate synthetase Proteins 0.000 claims 1
• 101001072091 Homo sapiens ProSAAS Proteins 0.000 claims 1
• 101000654674 Homo sapiens Semaphorin-6A Proteins 0.000 claims 1
• 101000685689 Homo sapiens Solute carrier family 17 member 9 Proteins 0.000 claims 1
• 101000850431 Homo sapiens Synaptic vesicle membrane protein VAT-1 homolog Proteins 0.000 claims 1
• 239000009493 Hova Substances 0.000 claims 1
• VWFWJPJMAFRNET-MQWMPURMSA-N IACI Chemical compound C1=CC=C2C([C@@H](O)[C@@H]3CC4CCN3C[C@@H]4CC)=CC=NC2=C1NC(=O)C1=CC([125I])=C(N=[N+]=[N-])C=C1O VWFWJPJMAFRNET-MQWMPURMSA-N 0.000 claims 1
• 241000692870 Inachis io Species 0.000 claims 1
• 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 claims 1
• 241000764773 Inna Species 0.000 claims 1
• 241001580017 Jana Species 0.000 claims 1
• 240000004836 Justicia adhatoda Species 0.000 claims 1
• 101710148054 Ketol-acid reductoisomerase (NAD(+)) Proteins 0.000 claims 1
• 101710099070 Ketol-acid reductoisomerase (NAD(P)(+)) Proteins 0.000 claims 1
• 101710151482 Ketol-acid reductoisomerase (NADP(+)) Proteins 0.000 claims 1
• 240000008415 Lactuca sativa Species 0.000 claims 1
• 235000013628 Lantana involucrata Nutrition 0.000 claims 1
• 240000005183 Lantana involucrata Species 0.000 claims 1
• 229920004936 Lavsan® Polymers 0.000 claims 1
• 241000331980 Leptus Species 0.000 claims 1
• 241001134453 Lista Species 0.000 claims 1
• 241000286819 Malo Species 0.000 claims 1
• 240000002129 Malva sylvestris Species 0.000 claims 1
• 235000006770 Malva sylvestris Nutrition 0.000 claims 1
• 241000124008 Mammalia Species 0.000 claims 1
• 239000009566 Mao-to Substances 0.000 claims 1
• 241000751119 Mila <angiosperm> Species 0.000 claims 1
• 241001077660 Molo Species 0.000 claims 1
• 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 claims 1
• 244000131360 Morinda citrifolia Species 0.000 claims 1
• 101100440233 Mus musculus Cmpk2 gene Proteins 0.000 claims 1
• 101001016849 Mus musculus Heat shock protein HSP 90-alpha Proteins 0.000 claims 1
• 101000985444 Mus musculus Heat shock protein HSP 90-beta Proteins 0.000 claims 1
• 101100237844 Mus musculus Mmp19 gene Proteins 0.000 claims 1
• 101100462972 Mus musculus Pcdh8 gene Proteins 0.000 claims 1
• 101100258095 Mus musculus Stum gene Proteins 0.000 claims 1
• MMOXZBCLCQITDF-UHFFFAOYSA-N N,N-diethyl-m-toluamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C)=C1 MMOXZBCLCQITDF-UHFFFAOYSA-N 0.000 claims 1
• XQVWYOYUZDUNRW-UHFFFAOYSA-N N-Phenyl-1-naphthylamine Chemical compound C=1C=CC2=CC=CC=C2C=1NC1=CC=CC=C1 XQVWYOYUZDUNRW-UHFFFAOYSA-N 0.000 claims 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims 1
• 102100032380 N-acetylaspartate synthetase Human genes 0.000 claims 1
• GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 claims 1
• 241000737052 Naso hexacanthus Species 0.000 claims 1
• 241000511989 Neomys Species 0.000 claims 1
• DTAFLBZLAZYRDX-UHFFFAOYSA-N OOOOOO Chemical compound OOOOOO DTAFLBZLAZYRDX-UHFFFAOYSA-N 0.000 claims 1
• 240000007817 Olea europaea Species 0.000 claims 1
• 241000277269 Oncorhynchus masou Species 0.000 claims 1
• 240000007594 Oryza sativa Species 0.000 claims 1
• 235000007164 Oryza sativa Nutrition 0.000 claims 1
• 241000950458 Oxandra laurifolia Species 0.000 claims 1
• CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims 1
• 241000282322 Panthera Species 0.000 claims 1
• 241001320145 Papaya lethal yellowing virus Species 0.000 claims 1
• 241001668545 Pascopyrum Species 0.000 claims 1
• 241001256807 Pasma Species 0.000 claims 1
• 239000006002 Pepper Substances 0.000 claims 1
• 241001387976 Pera Species 0.000 claims 1
• 235000008673 Persea americana Nutrition 0.000 claims 1
• 244000025272 Persea americana Species 0.000 claims 1
• 235000016761 Piper aduncum Nutrition 0.000 claims 1
• 240000003889 Piper guineense Species 0.000 claims 1
• 235000017804 Piper guineense Nutrition 0.000 claims 1
• 235000008184 Piper nigrum Nutrition 0.000 claims 1
• 241000320996 Poeta Species 0.000 claims 1
• 241000219000 Populus Species 0.000 claims 1
• 102100036366 ProSAAS Human genes 0.000 claims 1
• 241000219492 Quercus Species 0.000 claims 1
• 241000269435 Rana <genus> Species 0.000 claims 1
• 208000032411 Refractory with Excess of Blasts Anemia Diseases 0.000 claims 1
• 241000923660 Rorippa sylvestris Species 0.000 claims 1
• 235000002492 Rungia klossii Nutrition 0.000 claims 1
• 244000117054 Rungia klossii Species 0.000 claims 1
• 235000003976 Ruta Nutrition 0.000 claims 1
• 240000005746 Ruta graveolens Species 0.000 claims 1
• 241001080167 Salatis Species 0.000 claims 1
• 102100032795 Semaphorin-6A Human genes 0.000 claims 1
• 241000801924 Sena Species 0.000 claims 1
• 241000270295 Serpentes Species 0.000 claims 1
• 229940122605 Short-acting muscarinic antagonist Drugs 0.000 claims 1
• 240000003768 Solanum lycopersicum Species 0.000 claims 1
• 102100023106 Solute carrier family 17 member 9 Human genes 0.000 claims 1
• 206010041349 Somnolence Diseases 0.000 claims 1
• 208000005392 Spasm Diseases 0.000 claims 1
• 235000009337 Spinacia oleracea Nutrition 0.000 claims 1
• 244000300264 Spinacia oleracea Species 0.000 claims 1
• 235000018087 Spondias lutea Nutrition 0.000 claims 1
• 241000282887 Suidae Species 0.000 claims 1
• 102100033475 Synaptic vesicle membrane protein VAT-1 homolog Human genes 0.000 claims 1
• 241001441723 Takifugu Species 0.000 claims 1
• 241000188156 Tamu Species 0.000 claims 1
• 241000375392 Tana Species 0.000 claims 1
• 241000019011 Tasa Species 0.000 claims 1
• 244000269722 Thea sinensis Species 0.000 claims 1
• 235000009470 Theobroma cacao Nutrition 0.000 claims 1
• 244000299461 Theobroma cacao Species 0.000 claims 1
• 241000656145 Thyrsites atun Species 0.000 claims 1
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
• 241001125862 Tinca tinca Species 0.000 claims 1
• 235000006732 Torreya nucifera Nutrition 0.000 claims 1
• 244000111306 Torreya nucifera Species 0.000 claims 1
• 241001389010 Tuta Species 0.000 claims 1
• 235000015414 Urena lobata Nutrition 0.000 claims 1
• 240000006064 Urena lobata Species 0.000 claims 1
• 241000750042 Vini Species 0.000 claims 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 claims 1
• 241000482268 Zea mays subsp. mays Species 0.000 claims 1
• OIBDVHSTOUGZTJ-PEBLQZBPSA-N [(2r,3r,4s,5s,6s)-3,4,6-triacetyloxy-5-(trifluoromethylsulfonyloxy)oxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@@H](OC(C)=O)[C@@H](OS(=O)(=O)C(F)(F)F)[C@@H](OC(C)=O)[C@@H]1OC(C)=O OIBDVHSTOUGZTJ-PEBLQZBPSA-N 0.000 claims 1
• 210000001015 abdomen Anatomy 0.000 claims 1
• 239000011717 all-trans-retinol Substances 0.000 claims 1
• 235000019169 all-trans-retinol Nutrition 0.000 claims 1
• 239000000956 alloy Substances 0.000 claims 1
• 229910045601 alloy Inorganic materials 0.000 claims 1
• 208000004631 alopecia areata Diseases 0.000 claims 1
• RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 claims 1
• 210000000481 breast Anatomy 0.000 claims 1
• 239000012267 brine Substances 0.000 claims 1
• 244000309464 bull Species 0.000 claims 1
• 235000009120 camo Nutrition 0.000 claims 1
• 239000004202 carbamide Substances 0.000 claims 1
• 241001233037 catfish Species 0.000 claims 1
• 235000005607 chanvre indien Nutrition 0.000 claims 1
• 230000003749 cleanliness Effects 0.000 claims 1
• 235000014510 cooky Nutrition 0.000 claims 1
• 239000013256 coordination polymer Substances 0.000 claims 1
• 239000004914 cyclooctane Substances 0.000 claims 1
• 201000003146 cystitis Diseases 0.000 claims 1
• IWEDIXLBFLAXBO-UHFFFAOYSA-N dicamba Chemical compound COC1=C(Cl)C=CC(Cl)=C1C(O)=O IWEDIXLBFLAXBO-UHFFFAOYSA-N 0.000 claims 1
• JNSGIVNNHKGGRU-JYRVWZFOSA-N diethoxyphosphinothioyl (2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetate Chemical compound CCOP(=S)(OCC)OC(=O)C(=N/OC)\C1=CSC(N)=N1 JNSGIVNNHKGGRU-JYRVWZFOSA-N 0.000 claims 1
• CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 claims 1
• 101150010415 eat-5 gene Proteins 0.000 claims 1
• 206010015037 epilepsy Diseases 0.000 claims 1
• NYPJDWWKZLNGGM-RPWUZVMVSA-N esfenvalerate Chemical compound C=1C([C@@H](C#N)OC(=O)[C@@H](C(C)C)C=2C=CC(Cl)=CC=2)=CC=CC=1OC1=CC=CC=C1 NYPJDWWKZLNGGM-RPWUZVMVSA-N 0.000 claims 1
• 230000003203 everyday effect Effects 0.000 claims 1
• 235000013312 flour Nutrition 0.000 claims 1
• 210000001061 forehead Anatomy 0.000 claims 1
• 210000003128 head Anatomy 0.000 claims 1
• 239000011487 hemp Substances 0.000 claims 1
• 244000144980 herd Species 0.000 claims 1
• 235000015243 ice cream Nutrition 0.000 claims 1
• 208000017482 infantile neuronal ceroid lipofuscinosis Diseases 0.000 claims 1
• 235000015110 jellies Nutrition 0.000 claims 1
• 239000008274 jelly Substances 0.000 claims 1
• 235000020131 mattha Nutrition 0.000 claims 1
• PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims 1
• 230000028161 membrane depolarization Effects 0.000 claims 1
• QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims 1
• 229910052753 mercury Inorganic materials 0.000 claims 1
• STEPQTYSZVCJPV-UHFFFAOYSA-N metazachlor Chemical compound CC1=CC=CC(C)=C1N(C(=O)CCl)CN1N=CC=C1 STEPQTYSZVCJPV-UHFFFAOYSA-N 0.000 claims 1
• MJFJKKXQDNNUJF-UHFFFAOYSA-N metixene Chemical compound C1N(C)CCCC1CC1C2=CC=CC=C2SC2=CC=CC=C21 MJFJKKXQDNNUJF-UHFFFAOYSA-N 0.000 claims 1
• 239000003595 mist Substances 0.000 claims 1
• 235000013379 molasses Nutrition 0.000 claims 1
• 229940028444 muse Drugs 0.000 claims 1
• XEPXGZZWVKNRGS-GQYPCLOQSA-N n-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]octanamide Chemical compound CCCCCCCC(=O)NC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XEPXGZZWVKNRGS-GQYPCLOQSA-N 0.000 claims 1
• XPKWQNJZXXITJD-UHFFFAOYSA-N n-[5-amino-4-[6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-2-[3,5-dihydroxy-6-(hydroxymethyl)-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-3-hydroxycyclohexyl]icosanamide Chemical compound OC1C(OC2C(C(NC(=O)C(F)(F)F)C(O)C(CO)O2)O)C(NC(=O)CCCCCCCCCCCCCCCCCCC)CC(N)C1OC1OC(CN)C(O)C(O)C1O XPKWQNJZXXITJD-UHFFFAOYSA-N 0.000 claims 1
• 238000004651 near-field scanning optical microscopy Methods 0.000 claims 1
• 229910052754 neon Inorganic materials 0.000 claims 1
• GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 claims 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
• 235000017524 noni Nutrition 0.000 claims 1
• 229960000988 nystatin Drugs 0.000 claims 1
• VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims 1
• 108010014561 ovomucoid inhibitors Proteins 0.000 claims 1
• 239000005022 packaging material Substances 0.000 claims 1
• 210000003254 palate Anatomy 0.000 claims 1
• 239000003415 peat Substances 0.000 claims 1
• 235000021018 plums Nutrition 0.000 claims 1
• 235000015277 pork Nutrition 0.000 claims 1
• 230000004481 post-translational protein modification Effects 0.000 claims 1
• 239000000843 powder Substances 0.000 claims 1
• 244000062645 predators Species 0.000 claims 1
• GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims 1
• 229910052704 radon Inorganic materials 0.000 claims 1
• SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 claims 1
• 239000011347 resin Substances 0.000 claims 1
• 229920005989 resin Polymers 0.000 claims 1
• 235000009566 rice Nutrition 0.000 claims 1
• 239000011435 rock Substances 0.000 claims 1
• 235000005806 ruta Nutrition 0.000 claims 1
• 235000012045 salad Nutrition 0.000 claims 1
• 235000019515 salmon Nutrition 0.000 claims 1
• 235000013580 sausages Nutrition 0.000 claims 1
• 239000013049 sediment Substances 0.000 claims 1
• 210000000582 semen Anatomy 0.000 claims 1
• 235000020046 sherry Nutrition 0.000 claims 1
• 235000011888 snacks Nutrition 0.000 claims 1
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims 1
• 229940061368 sonata Drugs 0.000 claims 1
• 239000004071 soot Substances 0.000 claims 1
• 210000004243 sweat Anatomy 0.000 claims 1
• 229910052715 tantalum Inorganic materials 0.000 claims 1
• GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims 1
• 235000012976 tarts Nutrition 0.000 claims 1
• 235000013529 tequila Nutrition 0.000 claims 1
• QIWDGSYHBCMXSI-UHFFFAOYSA-J tetrasodium;(2-methyl-4-phosphonatooxynaphthalen-1-yl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].C1=CC=CC2=C(OP([O-])([O-])=O)C(C)=CC(OP([O-])([O-])=O)=C21 QIWDGSYHBCMXSI-UHFFFAOYSA-J 0.000 claims 1
• HADKRTWCOYPCPH-UHFFFAOYSA-M trimethylphenylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C1=CC=CC=C1 HADKRTWCOYPCPH-UHFFFAOYSA-M 0.000 claims 1
• 210000002700 urine Anatomy 0.000 claims 1
• 239000002966 varnish Substances 0.000 claims 1
• 235000015041 whisky Nutrition 0.000 claims 1
• 235000014101 wine Nutrition 0.000 claims 1
• 210000002268 wool Anatomy 0.000 claims 1
• 108090000765 processed proteins & peptides Proteins 0.000 abstract description 229
• 102000004196 processed proteins & peptides Human genes 0.000 abstract description 226
• 230000001105 regulatory effect Effects 0.000 abstract description 17
• 238000011031 large-scale manufacturing process Methods 0.000 abstract description 3
• 235000018102 proteins Nutrition 0.000 description 249
• 229920001184 polypeptide Polymers 0.000 description 225
• 108020004414 DNA Proteins 0.000 description 82
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 51
• 230000000694 effects Effects 0.000 description 51
• 230000004927 fusion Effects 0.000 description 46
• 230000027455 binding Effects 0.000 description 40
• 238000009739 binding Methods 0.000 description 40
• 230000011664 signaling Effects 0.000 description 32
• 235000001014 amino acid Nutrition 0.000 description 31
• 239000003814 drug Substances 0.000 description 28
• 229940024606 amino acid Drugs 0.000 description 25
• 150000001413 amino acids Chemical class 0.000 description 25
• 210000002966 serum Anatomy 0.000 description 25
• 229940079593 drug Drugs 0.000 description 22
• 230000012010 growth Effects 0.000 description 22
• 102000040430 polynucleotide Human genes 0.000 description 21
• 108091033319 polynucleotide Proteins 0.000 description 21
• 239000002157 polynucleotide Substances 0.000 description 21
• 239000008194 pharmaceutical composition Substances 0.000 description 20
• 241000282567 Macaca fascicularis Species 0.000 description 19
• 241001465754 Metazoa Species 0.000 description 19
• 239000003755 preservative agent Substances 0.000 description 19
• 235000018977 lysine Nutrition 0.000 description 18
• JLESVLCTIOAHPT-UHFFFAOYSA-N mmai Chemical compound C1=C(C)C(OC)=CC2=C1CC(N)C2 JLESVLCTIOAHPT-UHFFFAOYSA-N 0.000 description 17
• 238000009101 premedication Methods 0.000 description 17
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 16
• -1 M2970 Chemical compound 0.000 description 16
• 230000001225 therapeutic effect Effects 0.000 description 15
• 239000000833 heterodimer Substances 0.000 description 14
• 239000012634 fragment Substances 0.000 description 13
• 239000000047 product Substances 0.000 description 13
• 241000282553 Macaca Species 0.000 description 12
• 229910019567 Re Re Inorganic materials 0.000 description 12
• 230000015572 biosynthetic process Effects 0.000 description 12
• 238000004422 calculation algorithm Methods 0.000 description 12
• 108010076504 Protein Sorting Signals Proteins 0.000 description 11
• 235000018417 cysteine Nutrition 0.000 description 11
• 239000002552 dosage form Substances 0.000 description 11
• 238000002360 preparation method Methods 0.000 description 11
• 230000002335 preservative effect Effects 0.000 description 11
• 230000002035 prolonged effect Effects 0.000 description 11
• 238000000746 purification Methods 0.000 description 11
• 239000000243 solution Substances 0.000 description 11
• 239000003963 antioxidant agent Substances 0.000 description 10
• 235000006708 antioxidants Nutrition 0.000 description 10
• 238000006243 chemical reaction Methods 0.000 description 10
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 10
• 239000007788 liquid Substances 0.000 description 10
• 239000002609 medium Substances 0.000 description 10
• 238000003752 polymerase chain reaction Methods 0.000 description 10
• 239000000523 sample Substances 0.000 description 10
• 241000282412 Homo Species 0.000 description 9
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
• 230000002776 aggregation Effects 0.000 description 9
• 238000004220 aggregation Methods 0.000 description 9
• 239000003623 enhancer Substances 0.000 description 9
• 102000005962 receptors Human genes 0.000 description 9
• 108020003175 receptors Proteins 0.000 description 9
• 239000004471 Glycine Substances 0.000 description 8
• 230000004913 activation Effects 0.000 description 8
• 238000004458 analytical method Methods 0.000 description 8
• 238000003780 insertion Methods 0.000 description 8
• 230000037431 insertion Effects 0.000 description 8
• 230000003993 interaction Effects 0.000 description 8
• 238000001990 intravenous administration Methods 0.000 description 8
• 210000004698 lymphocyte Anatomy 0.000 description 8
• 239000000463 material Substances 0.000 description 8
• 230000004048 modification Effects 0.000 description 8
• 238000012986 modification Methods 0.000 description 8
• 238000002703 mutagenesis Methods 0.000 description 8
• 231100000350 mutagenesis Toxicity 0.000 description 8
• 239000000546 pharmaceutical excipient Substances 0.000 description 8
• 239000002904 solvent Substances 0.000 description 8
• 241000894006 Bacteria Species 0.000 description 7
• 102220470904 Interferon-induced protein with tetratricopeptide repeats 5_K48E_mutation Human genes 0.000 description 7
• 239000002202 Polyethylene glycol Substances 0.000 description 7
• 125000000539 amino acid group Chemical group 0.000 description 7
• 210000001772 blood platelet Anatomy 0.000 description 7
• 150000001720 carbohydrates Chemical class 0.000 description 7
• 238000000684 flow cytometry Methods 0.000 description 7
• 238000009472 formulation Methods 0.000 description 7
• 239000000710 homodimer Substances 0.000 description 7
• 238000004519 manufacturing process Methods 0.000 description 7
• 230000026731 phosphorylation Effects 0.000 description 7
• 238000006366 phosphorylation reaction Methods 0.000 description 7
• 229920001223 polyethylene glycol Polymers 0.000 description 7
• 229920005862 polyol Polymers 0.000 description 7
• 150000003077 polyols Chemical class 0.000 description 7
• 102200038856 rs150565592 Human genes 0.000 description 7
• 235000000346 sugar Nutrition 0.000 description 7
• 208000011580 syndromic disease Diseases 0.000 description 7
• 238000004448 titration Methods 0.000 description 7
• 238000013518 transcription Methods 0.000 description 7
• 230000035897 transcription Effects 0.000 description 7
• 239000004475 Arginine Substances 0.000 description 6
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 6
• 102000002265 Human Growth Hormone Human genes 0.000 description 6
• 108010000521 Human Growth Hormone Proteins 0.000 description 6
• 239000000854 Human Growth Hormone Substances 0.000 description 6
• 108091028043 Nucleic acid sequence Proteins 0.000 description 6
• 108091034117 Oligonucleotide Proteins 0.000 description 6
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 229930006000 Sucrose Natural products 0.000 description 6
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
• 230000001363 autoimmune Effects 0.000 description 6
• 238000003776 cleavage reaction Methods 0.000 description 6
• 230000000875 corresponding effect Effects 0.000 description 6
• 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 6
• 238000011161 development Methods 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 235000013930 proline Nutrition 0.000 description 6
• 230000017854 proteolysis Effects 0.000 description 6
• 230000007017 scission Effects 0.000 description 6
• 239000000600 sorbitol Substances 0.000 description 6
• 235000010356 sorbitol Nutrition 0.000 description 6
• 230000000638 stimulation Effects 0.000 description 6
• 239000005720 sucrose Substances 0.000 description 6
• 239000004094 surface-active agent Substances 0.000 description 6
• 210000001519 tissue Anatomy 0.000 description 6
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
• 108091026890 Coding region Proteins 0.000 description 5
• 108020004705 Codon Proteins 0.000 description 5
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 5
• 229930195725 Mannitol Natural products 0.000 description 5
• 241000700605 Viruses Species 0.000 description 5
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
• 235000009697 arginine Nutrition 0.000 description 5
• 235000009582 asparagine Nutrition 0.000 description 5
• 229960001230 asparagine Drugs 0.000 description 5
• 238000003556 assay Methods 0.000 description 5
• 230000004071 biological effect Effects 0.000 description 5
• 238000004364 calculation method Methods 0.000 description 5
• 235000014633 carbohydrates Nutrition 0.000 description 5
• 238000010367 cloning Methods 0.000 description 5
• 239000013078 crystal Substances 0.000 description 5
• 238000010494 dissociation reaction Methods 0.000 description 5
• 230000005593 dissociations Effects 0.000 description 5
• 238000005516 engineering process Methods 0.000 description 5
• 210000003979 eosinophil Anatomy 0.000 description 5
• 239000001963 growth medium Substances 0.000 description 5
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 5
• 230000000366 juvenile effect Effects 0.000 description 5
• 239000000594 mannitol Substances 0.000 description 5
• 235000010355 mannitol Nutrition 0.000 description 5
• 208000015994 miscarriage Diseases 0.000 description 5
• 239000002773 nucleotide Substances 0.000 description 5
• 125000003729 nucleotide group Chemical group 0.000 description 5
• 229920000136 polysorbate Polymers 0.000 description 5
• 238000011084 recovery Methods 0.000 description 5
• 230000010076 replication Effects 0.000 description 5
• 238000012216 screening Methods 0.000 description 5
• 238000007920 subcutaneous administration Methods 0.000 description 5
• 150000008163 sugars Chemical class 0.000 description 5
• 230000004083 survival effect Effects 0.000 description 5
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
• PFFIDZXUXFLSSR-UHFFFAOYSA-N 1-methyl-N-[2-(4-methylpentan-2-yl)-3-thienyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound S1C=CC(NC(=O)C=2C(=NN(C)C=2)C(F)(F)F)=C1C(C)CC(C)C PFFIDZXUXFLSSR-UHFFFAOYSA-N 0.000 description 4
• 241000238017 Astacoidea Species 0.000 description 4
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
• 241000238631 Hexapoda Species 0.000 description 4
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
• 206010061218 Inflammation Diseases 0.000 description 4
• 102220476527 Interleukin-18_M69A_mutation Human genes 0.000 description 4
• 208000003456 Juvenile Arthritis Diseases 0.000 description 4
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
• 230000004989 O-glycosylation Effects 0.000 description 4
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
• 206010037660 Pyrexia Diseases 0.000 description 4
• 241000555745 Sciuridae Species 0.000 description 4
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
• 239000004473 Threonine Substances 0.000 description 4
• 102220519976 [3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial_M88L_mutation Human genes 0.000 description 4
• 238000007792 addition Methods 0.000 description 4
• 230000003321 amplification Effects 0.000 description 4
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 4
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
• 238000001212 derivatisation Methods 0.000 description 4
• 238000013461 design Methods 0.000 description 4
• 238000006471 dimerization reaction Methods 0.000 description 4
• 230000009881 electrostatic interaction Effects 0.000 description 4
• 210000003743 erythrocyte Anatomy 0.000 description 4
• 239000008103 glucose Substances 0.000 description 4
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 4
• 230000005847 immunogenicity Effects 0.000 description 4
• 230000004054 inflammatory process Effects 0.000 description 4
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 4
• 230000014759 maintenance of location Effects 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• 230000001404 mediated effect Effects 0.000 description 4
• 238000002844 melting Methods 0.000 description 4
• 230000008018 melting Effects 0.000 description 4
• PKAHQJNJPDVTDP-UHFFFAOYSA-N methyl cyclopropanecarboxylate Chemical compound COC(=O)C1CC1 PKAHQJNJPDVTDP-UHFFFAOYSA-N 0.000 description 4
• 238000003199 nucleic acid amplification method Methods 0.000 description 4
• 235000015097 nutrients Nutrition 0.000 description 4
• 230000003285 pharmacodynamic effect Effects 0.000 description 4
• 229920000642 polymer Polymers 0.000 description 4
• 229940068965 polysorbates Drugs 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 208000002574 reactive arthritis Diseases 0.000 description 4
• 108091008146 restriction endonucleases Proteins 0.000 description 4
• 102220008853 rs193922308 Human genes 0.000 description 4
• 102200124879 rs28928898 Human genes 0.000 description 4
• 235000004400 serine Nutrition 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 235000015424 sodium Nutrition 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 239000003381 stabilizer Substances 0.000 description 4
• 238000010561 standard procedure Methods 0.000 description 4
• 230000004936 stimulating effect Effects 0.000 description 4
• 238000013268 sustained release Methods 0.000 description 4
• 239000012730 sustained-release form Substances 0.000 description 4
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 241000206602 Eukaryota Species 0.000 description 3
• 108010054147 Hemoglobins Proteins 0.000 description 3
• 102000001554 Hemoglobins Human genes 0.000 description 3
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
• 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 3
• 101100460719 Mus musculus Noto gene Proteins 0.000 description 3
• 102000035195 Peptidases Human genes 0.000 description 3
• 108091005804 Peptidases Proteins 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
• 101100187345 Xenopus laevis noto gene Proteins 0.000 description 3
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 239000000556 agonist Substances 0.000 description 3
• 102000025171 antigen binding proteins Human genes 0.000 description 3
• 108091000831 antigen binding proteins Proteins 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 206010003246 arthritis Diseases 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• 239000002585 base Substances 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
• 150000001718 carbodiimides Chemical class 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 230000010261 cell growth Effects 0.000 description 3
• 239000013592 cell lysate Substances 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 230000000295 complement effect Effects 0.000 description 3
• 150000001875 compounds Chemical class 0.000 description 3
• 201000001981 dermatomyositis Diseases 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• 239000000945 filler Substances 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 235000004554 glutamine Nutrition 0.000 description 3
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
• 230000006872 improvement Effects 0.000 description 3
• 238000002955 isolation Methods 0.000 description 3
• 210000000265 leukocyte Anatomy 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 238000004949 mass spectrometry Methods 0.000 description 3
• 229940126601 medicinal product Drugs 0.000 description 3
• 229910021645 metal ion Inorganic materials 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 239000013612 plasmid Substances 0.000 description 3
• 235000019833 protease Nutrition 0.000 description 3
• 238000003259 recombinant expression Methods 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 230000007781 signaling event Effects 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 238000010254 subcutaneous injection Methods 0.000 description 3
• 239000007929 subcutaneous injection Substances 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• 230000005030 transcription termination Effects 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• 241000701161 unidentified adenovirus Species 0.000 description 3
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
• VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 2
• SNTGWXAZMZPJPH-UHFFFAOYSA-N 1-(2,5-dioxopyrrolidin-1-yl)oxypyrrolidine-2,5-dione Chemical compound O=C1CCC(=O)N1ON1C(=O)CCC1=O SNTGWXAZMZPJPH-UHFFFAOYSA-N 0.000 description 2
• WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
• BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
• 206010003253 Arthritis enteropathic Diseases 0.000 description 2
• 206010003267 Arthritis reactive Diseases 0.000 description 2
• 208000036487 Arthropathies Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 238000012935 Averaging Methods 0.000 description 2
• 101100257262 Caenorhabditis elegans soc-1 gene Proteins 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
• QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 108010044091 Globulins Proteins 0.000 description 2
• 102000006395 Globulins Human genes 0.000 description 2
• 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
• 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
• 101000939500 Homo sapiens UBX domain-containing protein 11 Proteins 0.000 description 2
• 102000008100 Human Serum Albumin Human genes 0.000 description 2
• 108091006905 Human Serum Albumin Proteins 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 208000001953 Hypotension Diseases 0.000 description 2
• 206010022004 Influenza like illness Diseases 0.000 description 2
• 206010022095 Injection Site reaction Diseases 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
• 108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
• 108010002616 Interleukin-5 Proteins 0.000 description 2
• 102000000743 Interleukin-5 Human genes 0.000 description 2
• 108010002586 Interleukin-7 Proteins 0.000 description 2
• 102000000704 Interleukin-7 Human genes 0.000 description 2
• 208000012659 Joint disease Diseases 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
• 206010028813 Nausea Diseases 0.000 description 2
• 108010067372 Pancreatic elastase Proteins 0.000 description 2
• 206010036030 Polyarthritis Diseases 0.000 description 2
• 229920001213 Polysorbate 20 Polymers 0.000 description 2
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
• 102000001253 Protein Kinase Human genes 0.000 description 2
• RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 208000033464 Reiter syndrome Diseases 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• 208000034189 Sclerosis Diseases 0.000 description 2
• 108010071390 Serum Albumin Proteins 0.000 description 2
• 102000007562 Serum Albumin Human genes 0.000 description 2
• 239000004098 Tetracycline Substances 0.000 description 2
• NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 2
• 108020004440 Thymidine kinase Proteins 0.000 description 2
• 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
• YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 2
• 102100029645 UBX domain-containing protein 11 Human genes 0.000 description 2
• 241000711975 Vesicular stomatitis virus Species 0.000 description 2
• YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 239000008186 active pharmaceutical agent Substances 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 238000001261 affinity purification Methods 0.000 description 2
• 230000008484 agonism Effects 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 108010004469 allophycocyanin Proteins 0.000 description 2
• 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 229960000723 ampicillin Drugs 0.000 description 2
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
• 230000000845 anti-microbial effect Effects 0.000 description 2
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
• 239000000427 antigen Substances 0.000 description 2
• 108091007433 antigens Proteins 0.000 description 2
• 102000036639 antigens Human genes 0.000 description 2
• 230000003078 antioxidant effect Effects 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 235000003704 aspartic acid Nutrition 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 230000001588 bifunctional effect Effects 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 238000002701 cell growth assay Methods 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 239000003638 chemical reducing agent Substances 0.000 description 2
• 229940107161 cholesterol Drugs 0.000 description 2
• 235000012000 cholesterol Nutrition 0.000 description 2
• 208000019069 chronic childhood arthritis Diseases 0.000 description 2
• 238000004440 column chromatography Methods 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 230000022811 deglycosylation Effects 0.000 description 2
• 230000000368 destabilizing effect Effects 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 210000003162 effector t lymphocyte Anatomy 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 206010014910 enthesopathy Diseases 0.000 description 2
• 238000006911 enzymatic reaction Methods 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 238000004108 freeze drying Methods 0.000 description 2
• 230000033581 fucosylation Effects 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 230000036252 glycation Effects 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 238000005534 hematocrit Methods 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 230000036543 hypotension Effects 0.000 description 2
• 150000002463 imidates Chemical class 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 238000003018 immunoassay Methods 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000036512 infertility Effects 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 229940100994 interleukin-7 Drugs 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 229960000318 kanamycin Drugs 0.000 description 2
• 229930027917 kanamycin Natural products 0.000 description 2
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
• 229930182823 kanamycin A Natural products 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 210000003292 kidney cell Anatomy 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 229920002521 macromolecule Polymers 0.000 description 2
• 210000005075 mammary gland Anatomy 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 239000011859 microparticle Substances 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 210000000066 myeloid cell Anatomy 0.000 description 2
• 230000008693 nausea Effects 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 238000010525 oxidative degradation reaction Methods 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 230000002085 persistent effect Effects 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
• 229920000747 poly(lactic acid) Polymers 0.000 description 2
• 208000030428 polyarticular arthritis Diseases 0.000 description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
• 229940068977 polysorbate 20 Drugs 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 230000004845 protein aggregation Effects 0.000 description 2
• 108060006633 protein kinase Proteins 0.000 description 2
• NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 201000009890 sinusitis Diseases 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
• 238000001179 sorption measurement Methods 0.000 description 2
• 230000001954 sterilising effect Effects 0.000 description 2
• 238000004659 sterilization and disinfection Methods 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 150000005846 sugar alcohols Polymers 0.000 description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
• 229960002180 tetracycline Drugs 0.000 description 2
• 229930101283 tetracycline Natural products 0.000 description 2
• 235000019364 tetracycline Nutrition 0.000 description 2
• 150000003522 tetracyclines Chemical class 0.000 description 2
• 125000003396 thiol group Chemical group [H]S* 0.000 description 2
• 229940104230 thymidine Drugs 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
• QBFQXAKABOKEHT-JTQLQIEISA-N (2s)-3-(4-acetyloxyphenyl)-2-azaniumylpropanoate Chemical compound CC(=O)OC1=CC=C(C[C@H](N)C(O)=O)C=C1 QBFQXAKABOKEHT-JTQLQIEISA-N 0.000 description 1
• KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• WHBMMWSBFZVSSR-GSVOUGTGSA-N (R)-3-hydroxybutyric acid Chemical compound C[C@@H](O)CC(O)=O WHBMMWSBFZVSSR-GSVOUGTGSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
• 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
• BHANCCMWYDZQOR-UHFFFAOYSA-N 2-(methyldisulfanyl)pyridine Chemical compound CSSC1=CC=CC=N1 BHANCCMWYDZQOR-UHFFFAOYSA-N 0.000 description 1
• WRFHGDPIDHPWIQ-UHFFFAOYSA-N 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-n-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O=C1N(CC=2C=C(COCC)C(=CC=2)C=2C(=CC=CC=2)S(=O)(=O)NC=2C(=C(C)ON=2)C)C(CCCC)=NC21CCCC2 WRFHGDPIDHPWIQ-UHFFFAOYSA-N 0.000 description 1
• 102100026660 2-aminoethanethiol dioxygenase Human genes 0.000 description 1
• JQPFYXFVUKHERX-UHFFFAOYSA-N 2-hydroxy-2-cyclohexen-1-one Natural products OC1=CCCCC1=O JQPFYXFVUKHERX-UHFFFAOYSA-N 0.000 description 1
• BIGBDMFRWJRLGJ-UHFFFAOYSA-N 3-benzyl-1,5-didiazoniopenta-1,4-diene-2,4-diolate Chemical compound [N-]=[N+]=CC(=O)C(C(=O)C=[N+]=[N-])CC1=CC=CC=C1 BIGBDMFRWJRLGJ-UHFFFAOYSA-N 0.000 description 1
• ONZQYZKCUHFORE-UHFFFAOYSA-N 3-bromo-1,1,1-trifluoropropan-2-one Chemical compound FC(F)(F)C(=O)CBr ONZQYZKCUHFORE-UHFFFAOYSA-N 0.000 description 1
• QHSXWDVVFHXHHB-UHFFFAOYSA-N 3-nitro-2-[(3-nitropyridin-2-yl)disulfanyl]pyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1SSC1=NC=CC=C1[N+]([O-])=O QHSXWDVVFHXHHB-UHFFFAOYSA-N 0.000 description 1
• NLPWSMKACWGINL-UHFFFAOYSA-N 4-azido-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(N=[N+]=[N-])C=C1O NLPWSMKACWGINL-UHFFFAOYSA-N 0.000 description 1
• MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 description 1
• 229940117976 5-hydroxylysine Drugs 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
• 108010082126 Alanine transaminase Proteins 0.000 description 1
• 108010033918 Alanine-glyoxylate transaminase Proteins 0.000 description 1
• 239000004377 Alitame Substances 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 208000006820 Arthralgia Diseases 0.000 description 1
• 108010011485 Aspartame Proteins 0.000 description 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
• 241000713842 Avian sarcoma virus Species 0.000 description 1
• 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
• 241000701822 Bovine papillomavirus Species 0.000 description 1
• 240000002791 Brassica napus Species 0.000 description 1
• 235000011293 Brassica napus Nutrition 0.000 description 1
• 235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• 101100340271 Caenorhabditis elegans ida-1 gene Proteins 0.000 description 1
• 102000005600 Cathepsins Human genes 0.000 description 1
• 108010084457 Cathepsins Proteins 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 201000006082 Chickenpox Diseases 0.000 description 1
• 206010008531 Chills Diseases 0.000 description 1
• 206010068051 Chimerism Diseases 0.000 description 1
• GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 241000282552 Chlorocebus aethiops Species 0.000 description 1
• 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
• 206010008685 Chondritis Diseases 0.000 description 1
• 108010077544 Chromatin Proteins 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 241000238424 Crustacea Species 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• 102000016911 Deoxyribonucleases Human genes 0.000 description 1
• 108010053770 Deoxyribonucleases Proteins 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 108090000204 Dipeptidase 1 Proteins 0.000 description 1
• 238000008789 Direct Bilirubin Methods 0.000 description 1
• 206010065563 Eosinophilic bronchitis Diseases 0.000 description 1
• 206010064212 Eosinophilic oesophagitis Diseases 0.000 description 1
• 241000402754 Erythranthe moschata Species 0.000 description 1
• 206010015278 Erythrodermic psoriasis Diseases 0.000 description 1
• CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
• 239000001116 FEMA 4028 Substances 0.000 description 1
• 229940123457 Free radical scavenger Drugs 0.000 description 1
• 229930091371 Fructose Natural products 0.000 description 1
• 239000005715 Fructose Substances 0.000 description 1
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
• 102220499465 GRB10-interacting GYF protein 1_M65A_mutation Human genes 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 244000194101 Ginkgo biloba Species 0.000 description 1
• 235000008100 Ginkgo biloba Nutrition 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 101710154606 Hemagglutinin Proteins 0.000 description 1
• 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
• 241000711549 Hepacivirus C Species 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 1
• 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
• 241000701109 Human adenovirus 2 Species 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 208000008454 Hyperhidrosis Diseases 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
• 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 102100021496 Insulin-degrading enzyme Human genes 0.000 description 1
• 102100037850 Interferon gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 102000000589 Interleukin-1 Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102000003877 Interleukin-1 Type I Receptors Human genes 0.000 description 1
• 108010057368 Interleukin-1 Type I Receptors Proteins 0.000 description 1
• 102000003814 Interleukin-10 Human genes 0.000 description 1
• 108090000174 Interleukin-10 Proteins 0.000 description 1
• 102000003816 Interleukin-13 Human genes 0.000 description 1
• 108090000176 Interleukin-13 Proteins 0.000 description 1
• 102000004388 Interleukin-4 Human genes 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
• 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• 208000012528 Juvenile dermatomyositis Diseases 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 241000985627 Lota Species 0.000 description 1
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
• JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 101710107068 Myelin basic protein Proteins 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
• 241001325209 Nama Species 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
• 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
• 229940123973 Oxygen scavenger Drugs 0.000 description 1
• 108091006006 PEGylated Proteins Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 102000016387 Pancreatic elastase Human genes 0.000 description 1
• 241001631646 Papillomaviridae Species 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
• 241001505332 Polyomavirus sp. Species 0.000 description 1
• 208000037062 Polyps Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 101710176177 Protein A56 Proteins 0.000 description 1
• 208000003251 Pruritus Diseases 0.000 description 1
• 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 208000001431 Psychomotor Agitation Diseases 0.000 description 1
• 206010037575 Pustular psoriasis Diseases 0.000 description 1
• 101100288143 Rattus norvegicus Klkb1 gene Proteins 0.000 description 1
• 208000012322 Raynaud phenomenon Diseases 0.000 description 1
• 206010038743 Restlessness Diseases 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 108020004459 Small interfering RNA Proteins 0.000 description 1
• 108091081024 Start codon Proteins 0.000 description 1
• 208000034972 Sudden Infant Death Diseases 0.000 description 1
• 206010042440 Sudden infant death syndrome Diseases 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 230000006052 T cell proliferation Effects 0.000 description 1
• 230000005867 T cell response Effects 0.000 description 1
• 108010022394 Threonine synthase Proteins 0.000 description 1
• 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
• 108090000340 Transaminases Proteins 0.000 description 1
• 102220590292 Transcription factor 7-like 2_I19A_mutation Human genes 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 206010046980 Varicella Diseases 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 239000008351 acetate buffer Substances 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 229910001963 alkali metal nitrate Inorganic materials 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
• 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
• 150000001371 alpha-amino acids Chemical class 0.000 description 1
• 235000008206 alpha-amino acids Nutrition 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
• 235000011130 ammonium sulphate Nutrition 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 1
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
• 208000016063 arterial thoracic outlet syndrome Diseases 0.000 description 1
• 206010003230 arteritis Diseases 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
• 239000000605 aspartame Substances 0.000 description 1
• 235000010357 aspartame Nutrition 0.000 description 1
• 229960003438 aspartame Drugs 0.000 description 1
• 150000001510 aspartic acids Chemical class 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 244000052616 bacterial pathogen Species 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 229960004365 benzoic acid Drugs 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
• 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
• 102000006635 beta-lactamase Human genes 0.000 description 1
• 229960004853 betadex Drugs 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 239000001678 brown HT Substances 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 102220347667 c.283G>A Human genes 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 230000004856 capillary permeability Effects 0.000 description 1
• 125000000837 carbohydrate group Chemical group 0.000 description 1
• 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
• 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 230000003196 chaotropic effect Effects 0.000 description 1
• 238000002144 chemical decomposition reaction Methods 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 201000010415 childhood type dermatomyositis Diseases 0.000 description 1
• VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
• 229960003260 chlorhexidine Drugs 0.000 description 1
• VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
• FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
• 229940106681 chloroacetic acid Drugs 0.000 description 1
• 210000003483 chromatin Anatomy 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 238000000975 co-precipitation Methods 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 239000008139 complexing agent Substances 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000001054 cortical effect Effects 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 229940109239 creatinine Drugs 0.000 description 1
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Natural products CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 239000002577 cryoprotective agent Substances 0.000 description 1
• 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
• OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
• 230000009699 differential effect Effects 0.000 description 1
• 238000000113 differential scanning calorimetry Methods 0.000 description 1
• 102000004419 dihydrofolate reductase Human genes 0.000 description 1
• 210000001840 diploid cell Anatomy 0.000 description 1
• 238000000375 direct analysis in real time Methods 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
• 150000002019 disulfides Chemical group 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 108010067396 dornase alfa Proteins 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 229940088679 drug related substance Drugs 0.000 description 1
• 238000012063 dual-affinity re-targeting Methods 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 230000001516 effect on protein Effects 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 201000000708 eosinophilic esophagitis Diseases 0.000 description 1
• 210000001339 epidermal cell Anatomy 0.000 description 1
• YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
• 235000020774 essential nutrients Nutrition 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 230000005713 exacerbation Effects 0.000 description 1
• 206010016256 fatigue Diseases 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 238000012395 formulation development Methods 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000003209 gene knockout Methods 0.000 description 1
• 229940063135 genotropin Drugs 0.000 description 1
• 102000018146 globin Human genes 0.000 description 1
• 108060003196 globin Proteins 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 150000002338 glycosides Chemical class 0.000 description 1
• 230000001279 glycosylating effect Effects 0.000 description 1
• HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
• 210000002288 golgi apparatus Anatomy 0.000 description 1
• 230000001456 gonadotroph Effects 0.000 description 1
• ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
• 206010018797 guttate psoriasis Diseases 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 239000000185 hemagglutinin Substances 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 102000046949 human MSC Human genes 0.000 description 1
• 235000003642 hunger Nutrition 0.000 description 1
• 229920002674 hyaluronan Polymers 0.000 description 1
• 229960003160 hyaluronic acid Drugs 0.000 description 1
• 210000004408 hybridoma Anatomy 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 229960002163 hydrogen peroxide Drugs 0.000 description 1
• 229920001477 hydrophilic polymer Polymers 0.000 description 1
• 125000001165 hydrophobic group Chemical group 0.000 description 1
• 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
• 230000033444 hydroxylation Effects 0.000 description 1
• 238000005805 hydroxylation reaction Methods 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 210000003016 hypothalamus Anatomy 0.000 description 1
• 230000002631 hypothermal effect Effects 0.000 description 1
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
• 230000005934 immune activation Effects 0.000 description 1
• 230000008629 immune suppression Effects 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 238000013394 immunophenotyping Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 210000004964 innate lymphoid cell Anatomy 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 230000004068 intracellular signaling Effects 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
• 238000006317 isomerization reaction Methods 0.000 description 1
• 239000000644 isotonic solution Substances 0.000 description 1
• 229950003188 isovaleryl diethylamide Drugs 0.000 description 1
• 201000004990 juvenile ankylosing spondylitis Diseases 0.000 description 1
• 125000000468 ketone group Chemical group 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 230000001926 lymphatic effect Effects 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 229910001425 magnesium ion Inorganic materials 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• RMAHPRNLQIRHIJ-UHFFFAOYSA-N methyl carbamimidate Chemical compound COC(N)=N RMAHPRNLQIRHIJ-UHFFFAOYSA-N 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• NEGQCMNHXHSFGU-UHFFFAOYSA-N methyl pyridine-2-carboximidate Chemical compound COC(=N)C1=CC=CC=N1 NEGQCMNHXHSFGU-UHFFFAOYSA-N 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 108010065781 myosin light chain 2 Proteins 0.000 description 1
• 229950006780 n-acetylglucosamine Drugs 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 229940063137 norditropin Drugs 0.000 description 1
• 210000000299 nuclear matrix Anatomy 0.000 description 1
• 238000001668 nucleic acid synthesis Methods 0.000 description 1
• 229940063149 nutropin Drugs 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 238000012510 peptide mapping method Methods 0.000 description 1
• 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
• 150000002978 peroxides Chemical class 0.000 description 1
• 230000002688 persistence Effects 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 125000000405 phenylalanyl group Chemical group 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• HMFAQQIORZDPJG-UHFFFAOYSA-N phosphono 2-chloroacetate Chemical compound OP(O)(=O)OC(=O)CCl HMFAQQIORZDPJG-UHFFFAOYSA-N 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 238000003566 phosphorylation assay Methods 0.000 description 1
• 230000000865 phosphorylative effect Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920001993 poloxamer 188 Polymers 0.000 description 1
• 229940044519 poloxamer 188 Drugs 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 208000012102 polyarticular juvenile rheumatoid arthritis Diseases 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 229920002704 polyhistidine Polymers 0.000 description 1
• 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 210000004896 polypeptide structure Anatomy 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229950008882 polysorbate Drugs 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• 235000011164 potassium chloride Nutrition 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 230000009465 prokaryotic expression Effects 0.000 description 1
• 230000009696 proliferative response Effects 0.000 description 1
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 230000006318 protein oxidation Effects 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 238000001799 protein solubilization Methods 0.000 description 1
• 230000007925 protein solubilization Effects 0.000 description 1
• 230000029983 protein stabilization Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 229960003581 pyridoxal Drugs 0.000 description 1
• 235000008164 pyridoxal Nutrition 0.000 description 1
• 239000011674 pyridoxal Substances 0.000 description 1
• 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
• 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
• 229960001327 pyridoxal phosphate Drugs 0.000 description 1
• 239000002516 radical scavenger Substances 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 238000004064 recycling Methods 0.000 description 1
• 230000014493 regulation of gene expression Effects 0.000 description 1
• 239000003488 releasing hormone Substances 0.000 description 1
• 238000003571 reporter gene assay Methods 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 210000001995 reticulocyte Anatomy 0.000 description 1
• 101150089837 rot gene Proteins 0.000 description 1
• 102200066678 rs1554618767 Human genes 0.000 description 1
• 102200065347 rs193922539 Human genes 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 238000009938 salting Methods 0.000 description 1
• 238000005185 salting out Methods 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 208000010157 sclerosing cholangitis Diseases 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• 238000003567 signal transduction assay Methods 0.000 description 1
• 238000004088 simulation Methods 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 239000004055 small Interfering RNA Substances 0.000 description 1
• IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
• JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
• 235000010265 sodium sulphite Nutrition 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 229960004532 somatropin Drugs 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 230000003595 spectral effect Effects 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 239000012134 supernatant fraction Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 230000035900 sweating Effects 0.000 description 1
• 230000001839 systemic circulation Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 238000010257 thawing Methods 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 230000035922 thirst Effects 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• 102000014898 transaminase activity proteins Human genes 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 102000027257 transmembrane receptors Human genes 0.000 description 1
• 108091008578 transmembrane receptors Proteins 0.000 description 1
• ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 230000010415 tropism Effects 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1